Literature DB >> 1834799

Prevalence of HBsAg carriers in native and immigrant pregnant female populations in Israel and passive/active vaccination against HBV of newborns at risk.

V Bogomolski-Yahalom1, E Granot, N Linder, R Adler, S Korman, N Manny, R Tur-Kaspa, D Shouval.   

Abstract

Israel has no official prevention policy at present against perinatal and horizontal transmission of hepatitis B virus (HBV) infection in newborns and children at risk. The present study was designed to assess the prevalence of HBV carrier state in a population of 11,123 pregnant women at term. Among this population (mean age 29.7 +/- 5.9), 98 women (0.88%) were found to be asymptomatic HBsAg+ carriers, and 97% of these carriers were anti-HBe+. Evidence for HBV replication, as determined by serum HBV-DNA, was established in 6.6% of the HBsAg+/anti-HBe+ population. The HBsAg carrier rate was strongly influenced by religion, continent, and country of birth of the carrier mothers. The highest relative carrier rate was found among women of Moslem origin (4.3%), as compared to Jewish women (0.67%). Most carrier women were born in Israel (56.1%) to mothers who had emigrated from regions with intermediate or high endemicity of HBV, such as North Africa or the Middle East. In these groups, the HBsAg carrier rate ranged between 1.2 and 3.0%. Ninety-three percent of newborns receiving passive/active vaccination against HBV developed protective levels of anti-HBs. Finally, evidence for horizontal transmission of HBV was found in 19.3% of 83 non-vaccinated children in families of HBsAg carriers. The present study therefore establishes HBsAg prevalence rates in specific risk groups of women at term and confirms the need for an official policy on immunization against HBV in Israel. Since over 50% of women at term belong to the defined risk groups, universal active vaccination of the entire newborn population each year is suggested as the most rational and needed policy in Israel.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1834799     DOI: 10.1002/jmv.1890340404

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  4 in total

1.  Unexplained fever in neonates may be associated with hepatitis B vaccine.

Authors:  N Linder; M Raz; L Sirota; B Reichman; D Lubin; J Kuint; A H Cohen; A Barzilai
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1999-11       Impact factor: 5.747

2.  Cost-benefit analysis of a nationwide inoculation programme against viral hepatitis B in an area of intermediate endemicity.

Authors:  G M Ginsberg; S Berger; D Shouval
Journal:  Bull World Health Organ       Date:  1992       Impact factor: 9.408

3.  Hepatitis B carrier state among SLE patients: case-control study.

Authors:  Omer Gendelman; Naim Mahroum; Doron Comaneshter; Pnina Rotman-Pikielny; Arnon D Cohen; Howard Amital; Michael Sherf
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

4.  Prevalence of Hepatitis B Surface Antigen in Pregnant Women in Beheshti Hospital of Kashan, Isfahan.

Authors:  Hasan Afzali; Mansooreh Momen Heravi; Seyyed Alireza Moravveji; Maryam Poorrahnama
Journal:  Iran Red Crescent Med J       Date:  2015-07-22       Impact factor: 0.611

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.